Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Nancy G.B. Agrawal
Advertisement
Nancy G.B. Agrawal is vice-president, pharmacokinetics, pharmacodynamics, and drug metabolism, Merck.
Articles by Nancy G.B. Agrawal
Advertisement
Latest Updated Articles
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic ModelingPublished: March 16th 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
3
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
4
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
5
